Introduction
============

Ion channels are attractive drug targets and small molecule therapeutic drugs to this protein family generate worldwide sales of approximately \$12 billion ^[@ref-1]^. Despite this attraction and the demonstrated involvement of ion channel antibodies in diverse autoimmune diseases ^[@ref-2]^, no antibody-based ion channel therapeutic has progressed to the clinic, due to challenges in developing both optimal immunogens and robust screening processes to identify channel modulators ^[@ref-3]^.

The genetically validated pain target Na ~V~1.7 functions as a voltage-gated sodium channel expressed in nociceptive neurons in the peripheral nervous system ^[@ref-4]^. Na ~V~1.7 is comprised of four domains (DI-DIV), each containing six transmembrane (TMD) helices, in which TMD helices S1--S4 contain the voltage sensor region and TMD helices S5--S6 contain the pore region. Upon membrane depolarization, the voltage sensor domains, in particular the voltage sensor paddle comprised of S3, the S3--S4 loop, and S4, move outward resulting in pore opening, influx of sodium into the cell, and action potential firing ^[@ref-5]^. Recently, Lee *et al*. described a monoclonal antibody SVmab1 targeted to a peptide loop between DII S3-4 in the voltage sensor paddle region, which bound a Na ~V~1.7 DII voltage-sensor domain protein by ELISA and blocked Na ~V~1.7 function by electrophysiology ^[@ref-6]^. In particular, SVmab1, purified from a hybridoma, was reported to block human Na ~V~1.7 currents in a use-dependent manner, in which repeated channel opening events uncovered the epitope for antibody binding in the paddle region, akin to antibody blockade of potassium channels ^[@ref-6],\ [@ref-7]^. The antigen used to generate SVmab1 was peptide VELFLADVEG, located in the DII paddle region and the sequence of this antibody was previously reported ^[@ref-8]^.

We generated recombinant SVmab1 (rSVmab1) protein based on the publically available sequence information and evaluated its ability to bind peptide VELFLADVEG, purified DII voltage sensor domain protein, and cells expressing Na ~V~1.7, as well as block Na ~V~1.7 sodium currents in heterologous cells.

Methods
=======

Cloning, expression, and purification of rSVmab1 and control antibodies
-----------------------------------------------------------------------

The amino acid sequences for the heavy and light chains of rSVmab1 were obtained from Table 2 of a publication ^[@ref-8]^. The variable region heavy chain sequence corresponds to SEQ ID NO 4 and the variable region light chain sequence corresponds to SEQ ID NO 8 of this publication. Synthetic, human codon-optimized, reverse translated DNA was generated by Genewiz, and subcloned into pTT5 expression vectors (National Research Council Canada), containing murine IgG1 heavy chain or kappa light chain constant regions. The coding regions from the resulting constructs were confirmed by sequencing to match the published sequences ^[@ref-8]^. Plasmids were purified (Endofree Quanta Mega Kit; MDI Healthcare Services India) and re-confirmed by both sequencing and diagnostic restriction digest prior to transfection. Heavy and light chain DNA constructs for rSVmab1 were transiently co-transfected into 1.6L of HEK293 6E cells in an Erlenmeyer shake flask.

Cells were grown in Freestyle F17 media supplemented with 4mM L-glutamine, 0.1% pluronic acid and 1x antibiotic solution (Freestyle F17: Invitrogen, \#12338-026; L-glutamine: Himedia, \#TC243-1Kg; Antibiotic-Antimycotic: Invitrogen, \#15140-062; Pluronic F-68; Invitrogen, \#24040032; Tryptone N1: TekniScience Inc, \#19553). Transfections were performed using polyethylenimine (PEI; Polysciences, \#23967), at a DNA--PEI MAX ratio of 1:2.88. At 24 hours post-transfection, the cells were supplemented with 0.5% Tryptone. Cells were harvested after 5 days of culture and the supernatant was used for antibody purification. Conditioned media was clarified and used for affinity chromatography using a MabSelect SuRe column (GE Healthcare Life Sciences, \#17-5199-01). Fractions containing antibody were pooled and further purified by ion exchange chromatography using SP-Sepharose Fast Flow resin (GE Healthcare). Protein purification and integrity were monitored throughout by SDS-PAGE using 4--12% Bis-Tris gels (Invitrogen, \#NP0322), MES SDS Running Buffer (20X; Invitrogen, \#NP0002), LDS sample buffer (Invitrogen, \#NP0007) and stained with Simply Blue Safe (Invitrogen, \#LC6065). Purified antibody was buffer exchanged via dialysis into 10mM sodium acetate (pH5.2), containing 9% sucrose and concentrated (30kD Amicon Ultra centrifugal filter unit; Millipore, \#UFC801096). The concentration of the purified antibody was determined by the A280 method on a Nanodrop 2000c (Thermo Fisher Scientific). The final antibody sample was verified by analytical size exclusion chromatography-high performance liquid chromatography (SEC-HPLC) using a YMC-Pack Diol-200, 300 × 8 mm column (YMC Co. Ltd., ID: 0830002871 P/No. DL20S05-3008WT) equilibrated with 20mM sodium phosphate, 400mM sodium chloride, at a pH 7.2, maintaining a flow rate of 0.75ml/min. Finally, the rSVmab1 preparation was assayed for endotoxin levels using the Kinetic Endotoxin Assay (Charles River PTS Assay; 1.0-0.01 EU/ml Sensitivity PTS Cartridge, \#PTS2001F) and flash frozen in liquid nitrogen. The isotype-matched control antibody used for electrophysiology studies was a recombinant murine IgG1/kappa monoclonal derived from an unrelated immunization campaign. The positive control mouse monoclonal antibody, used for peptide and D2S domain binding ELISAs, was generated against the DII voltage sensor peptide sequence VELFLADVEG by Abmart, which corresponds to the exact sequence used to generate SVmab1.

Mass spectrometry
-----------------

Mass analysis of non-reduced rSVmab1 was performed on an Agilent TOF 6230 Mass Spectrometer coupled with an Agilent 1260 Infinity HPLC system. HPLC Mobile phases A and B were 0.1% trifluoroacetic acid (TFA) and 90% n-propanol/0.1% TFA, respectively. The reverse-phase column was an Agilent Zorbax 300SB-C8, 3.5µm 2.1 × 50mm column (\#865750-906), heated to 75°C. A 20µg aliquot of rSVmab1 was injected into the system. The sample was chromatographed at 0.2 ml/min with an 11 min gradient as follows: 20%B for 1 min; 20--70%B over 8 min; 70--100%B over 1 min; held at 100%B for 1 min. Mass spectrometer ionization and transmission settings were set as follows: Vcap, 5900V; fragmenter voltage, 460V; nebulizer gas, 25 psig; skimmer voltage, 95V; Oct RF Vpp voltage, 800V; and drying gas, 13 l/min.

Purification of human Na ~V~1.7 DII voltage sensor domain
---------------------------------------------------------

DNA encoding human Na ~V~1.7 amino acids 709--857 (GenScript; derived from sequence NM_002977.3; <https://www.ncbi.nlm.nih.gov/nuccore/NM_002977.3>; NCBI Nucleotide RRID: SCR_004860) was cloned N-terminal to a 6x histidine affinity tag \[D2S(709-857)-His ~6~\] in the pFastBac vector (Thermo Fisher Scientific), and a recombinant baculovirus was generated (Bac-to-Bac; Thermo Fisher Scientific). In total, 12L of Sf9 insect cells (3 × 10 ^6^ cell/ml; Expression Systems) were infected with 5% (v/v) virus, incubated at 27°C for 48 h in spinner flasks, harvested by centrifugation and stored at -80°C until use. The remainder of the purification was conducted at 4°C. The frozen cell pellet (175 g wet weight) was resuspended in lysis buffer \[25 mM Tris-HCl (pH 7.4), 200 mM NaCl (TBS), containing 1% v/v protease inhibitor cocktail (Sigma-Aldrich, Inc., \#P8340)\], stirred until thawed and disrupted by passing the suspension through a high pressure homogenizer at 10,000 psi (Microfluidizer M110EHI; Microfluidics, Corp.). The crude lysate was centrifuged at 10,000 × g for 15 min and the resulting supernatant collected and centrifuged at 100,000 × g for 1.5 h in a 70 Ti rotor. The supernatant was decanted and the 100,000 × g pellet was collected, resuspended in lysis buffer and homogenized prior to solubilization. N-dodecyl-β-D-maltoside (DDM; Anatrace, Inc.) was added to the resuspended membranes to a final concentration of 40 mM, incubated for 1h on a rocker, followed by centrifugation at 100,000 × g to pellet insoluble material. The DDM soluble fraction (100ml) was decanted and used for purification. Preparative chromatography steps were performed on an AKTA Purifier (GE Lifesciences, Inc.) in TBS containing 1 mM DDM, unless noted. SDS-PAGE with Coomassie Blue staining was used to monitor purification.

Analytical tryptophan fluorescence size exclusion chromatography (Trp FSEC) was used to monitor the oligomerization state of D2S(709-857)-His ~6~ during purification. Trp FSEC was performed on a Superose 6 10/300 GL column (GE Healthcare Life Sciences) equilibrated with DDM buffer, using an Agilent HPLC system equipped with a fluorescence detector (272 nm excitation/327 nm emission). Absorbance at 280nm was used to determine the protein concentration of purified D2S(709-857)-His ~6~. N-terminal amino acid sequencing confirmed the identity of purified D2S(709-857)-His ~6~. The DDM soluble fraction was incubated with 10ml Talon Superflow resin (Clontech) for 14--16h on a rocker. The resin was collected into an XK 16 column (GE Healthcare Life Sciences) and washed with stepwise increases in imidazole concentration (10 c.v., 5mM; 10 c.v., 7.5mM; 5 c.v., 15mM; and 2 c.v., 25mM) in DDM buffer until the A280nm reached a stable minimum. Talon-bound protein was eluted with 200mM imidazole in DDM buffer. Fractions containing D2S(709-857)-His ~6~ were pooled, concentrated in Ultracel-30K MWCO ultrafiltration units (Millipore Corp., Inc.) and chromatographed on a Superdex 200 10/300 column (GE Lifesciences, Inc.) to remove contaminating proteins and imidazole. The monodispersity of fractions containing D2S(709-857)-His ~6~ was confirmed by Trp FSEC ^[@ref-9]^. Monodisperse, micellar D2S(709-857)-His ~6~ migrates at an apparent MW of 70kDa, which is similar in size to DDM micelles. Thus, the detergent concentrates during ultrafiltration and cannot be separated well using size exclusion chromatography (SEC), necessitating another Talon affinity step. SEC fractions containing monodisperse D2S(709-857)-His ~6~ were pooled, and incubated with 0.5ml Talon resin for 2h. The resin was collected in a 2ml gravity column, washed, and protein was eluted with 200mM imidazole in DDM buffer. The eluate was loaded into a 0.5--3ml 10K MWCO Slide-a-Lyzer cassette (Thermo Fisher Scientific) and imidazole was removed by dialysis against DDM buffer. The dialyzed D2S(709-857)-His ~6~ was collected, aliquoted, and frozen at -80°C.

Generation of Na ~V~1.7 BacMam
------------------------------

A recombinant BacMam baculovirus expressing human Na ~V~1.7 was constructed as follows. A full-length cDNA clone of human Na ~V~1.7 was obtained from Origene (pCMV6-XL4-Na ~V~1.7) and codon optimized using synthetic DNAs (Thermo Fisher Scientific) to produce a cDNA that was stable during DNA propagation in *E. coli* strain HB101. The resulting cDNA was cloned into pENTR-D-Topo (Thermo Fisher Scientific) and the sequence was confirmed. pENTR-D-Topo-Na ~V~1.7 was used in an LR Gateway reaction with pHTBV1.1 to produce pHTBV1.1-Na ~V~1.7. After DNA sequence confirmation, pHTBV1.1-Na ~V~1.7 was used in a transposition reaction to generate recombinant full-length baculoviral genomic DNA carrying Na ~V~1.7, with transcription driven by the immediate early promoter from cytomegalovirus (Bac-to-Bac; Thermo Fisher Scientific). Transfection into Sf9 insect cells (Expression Systems) using FuGENE HD (Roche) allowed production of replication competent baculovirus, pseudotyped with VSV-G protein. The resulting transfection supernatant (P0 virus) was amplified twice, titered by endpoint dilution, as measured by gp64 expression (Expression Systems), and used in cell based assays.

Stable cell lines
-----------------

Human Na ~V~1.7 HEK293 stably transfected cells were purchased from Eurofins Pharma Bioanalytics Services US, Inc., and human Na ~V~1.7 CHO-K1 stably transfected, inducible cells were purchased from Chantest.

HEK293 complete media contained D-MEM/F-12 (1X) with 10% fetal bovine serum (FBS; US origin), 1x non-essential amino acids (NEAA; 10mM, 100X), 1x penicillin-streptomycin-glutamine (100X), and 400ug/ml Geneticin® Selective Antibiotic (all Invitrogen; \#11330-033, \#16000-044, 11140-050, 10378--016 and 10131-027, respectively).

CHO-K1 complete media contained F12 HAM (1X; Sigma-Aldrich, \#N6658) with 10% FBS (US origin; Sigma-Aldrich, \#F2442), 1x L-glutamine (Sigma-Aldrich, \#G7513), 0.4mg/ml Zeocin (Invitrogen, \#46-0509), and 0.01mg/ml blasticidin (Gibco, \#A11139-03). CHO-K1 stable cells were seeded at 8×6 ^10^ cells in 20ml media with 1ug/ml tetracycline (Sigma-Aldrich, \#T7660) and 100uM sodium butyrate (Sigma-Aldrich, \#303410) in a T-175 flask and incubated 18--24hr prior to FACS analysis.

BacMam transduction
-------------------

U-2 OS cells (ATCC; \#HTB-96; RRID: CVCL_0042), cultured to 80% confluency, were rinsed with Ca and Mg-free DPBS (Gibco, \#14190-144) and dissociated with Cell Dissociation Buffer (enzyme-free; Gibco, \#13151-014) for 8--10 minutes in a 37°C incubator. Following addition of 5.0ml of complete growth medium, cells were dislodged with gentle pipetting, pelleted, and resuspended to 3×6 ^10^ cells/5ml growth medium. Cells and human Na ~V~1.7 BacMam virus added at 200 MOI were combined in a T-75 flask and incubated 18-24hr prior to FACS analysis.

U-2 OS complete media contains McCoy's 5A with 10% FBS, 1x NEAA, 1x L-glutamine (200mM, 100X) and 1x penicillin-streptomycin (10,000U/ml, 100X) (all Gibco; \#16600-082, \#10099-141, \#11140-050, \#25030-081 and \#15140-122, respectively).

Peptide binding ELISAs
----------------------

The synthetic peptide VELFLADVEG (Abmart) was conjugated to maleimide-activated bovine serum albumin (BSA; Thermo Fisher Scientific, \#PI-77116) through an N-terminal cysteine. The peptide was reconstituted to 10 mg/ml in DMSO and maleimide-activated BSA was made up to 10 mg/ml in dH ~2~O. The BSA-conjugate was prepared by mixing 100ug of maleimide-activated BSA in 200uL PBS, 100ug synthetic peptide and 5mM TCEP (Thermo Fisher Scientific, \#PI-77720), and the reaction was incubated at room temperature overnight. BSA-conjugated synthetic peptide (VELFLADVEG) was coated at 1μg/ml on a Costar 384-well medium binding plate (\#3702) using 40μL/well, in 1X PBS and incubated at 37°C for 1hr. The plate was washed three times with 90μL/well 1X PBS using a Biotek plate washer (ELx 405), blocked with 1% milk/1X PBS (90μl/well), and incubated at room temperature for 30 min. Blocking buffer was aspirated and rSVmab1 or positive control mouse monoclonal antibody against the DII sensor peptide VELFLADVEG was titrated from 200nM using 40μL/well in 1X PBS/1% milk and incubated at room temperature for 1hr. Plates were washed three times with 90μL/well 1X PBS. Polyclonal goat anti-mouse Fc HRP (Jackson ImmunoResearch Labs, \#115-035-164; RRID: AB_2338510) was added at 100ng/mL in 1X PBS/1% milk (40μL/well) and incubated at room temperature for 1hr. Plates were washed an additional four times and the HRP signal was detected with 1-Step TMB (40μL/well; Neogenm \#308177) for 30min followed by quenching with 1N hydrochloric acid (40μL/well). Plates were read at OD450 (Thermo Multiskan Ascent).

Soluble DIIS binding ELISAs
---------------------------

Purified DIIS was coated at 2μg/ml on a 96-well NiNTA plate pre-blocked by the manufacturer with bovine serum albumin (Thermo Fisher Scientific, \#15442), (50μL/well), in 1X PBS/2mM n-dodecyl-β-D-maltoside (DDM) detergent (Calbiochem, 324355), and then incubated at 37°C for 1hr. Plates were washed twice with 200μL/well of 1X PBS/2mM DDM. rSVmab1 or positive control mouse monoclonal antibody against the DII sensor peptide VELFLADVEG was titrated 1:2 from 13nM in 1% milk/1X PBS/2mM DDM (50μL/well) and then incubated at room temperature for 1hr. Following two washes with 200μL/well of 1X PBS/2mM DDM, polyclonal goat anti-mouse Fc HRP (Jackson ImmunoResearch Labs, \#115-035-164; RRID: AB_2338510) was added at 400ng/mL in 1% milk/1X PBS/2mM DDM (50μL/well), and incubated at room temperature for 1hr. Plates were washed an additional four times and the HRP signal was detected with 1-step TMB (50μL/well), for 30min followed by quenching with 1N hydrochloric acid (50μL/well). Plates were read at OD450 (Thermo Multiskan Ascent).

FACS binding assays
-------------------

Human Na ~V~1.7 stably transfected HEK293 cells, human Na ~V~1.7 stably transfected, inducible CHO-K1 cells, human Na ~V~1.7 BacMam transduced U-2 OS and parental cells were treated with non-enzymatic dissociation buffer (Sigma-Aldrich, \#C5914) to remove cells from the flask prior to FACS assays. In 96-well V-bottom plates (Costar, \#3897), 50,000 cells/well were incubated with 33nM rSVmab1 or isotype control (R&D Systems, \#MAB002; RRID: AB_357344; monoclonal mouse IgG1 isotype control) or positive control antibodies (Millipore, \#MABN41; RRID: AB_10808664; monoclonal mouse anti-human Na ~V~1.7 antibody ^[@ref-10]^) in 50ul of FACS buffer (1X PBS+2% FBS; PBS: Hyclone, \#SH30256.02; FBS: Sigma-Aldrich, \#F2442, 500mL), and then incubated at 4 ^°^C for 1hr. Cells were isolated by centrifugation at 2500 RPM (664xg) for 2 min, the supernatant was removed and the cells were washed twice with 200ul/well FACS buffer. Cells were resuspended in 50ul (5ug/ml) polyclonal goat-anti-mouse IgG Fc Alexa 647 (Jackson ImmunoResearch Labs, \#115-605-071; RRID: AB_2338909) and 2.5ug/ml 7-aminoactinomycin D (7AAD; Sigma, \#A9400) and incubated at 4 ^°^C for 15min. Cells were then washed once, resuspended in 50ul FACS buffer and read on a Becton Dickenson Accuri Flow Cytometer using the Intellicyt Hypercyt Autosampler. Single cells were gated and geometric means (GeoMean) of 7AAD-negative cells were analyzed using the Intellicyte Forecyt 3.1 software (Intellicyt; <http://intellicyt.com/products/software/>). A minimum of 350 live cell events were collected per well.

Manual patch clamp electrophysiology
------------------------------------

Human Na ~V~1.7 stably transfected HEK293 cells, plated on glass coverslips (Warner Instruments, CS-8R, \#64-0701) for 18--28 hr before recording, were voltage clamped using the whole cell patch clamp configuration at room temperature (21--24°C), using a MultiClamp 700B amplifier and DIGIDATA 1322A with pCLAMP 10.2 software (Molecular Devices; <https://www.moleculardevices.com/systems/conventional-patch-clamp/pclamp-10-software>; RRID: SCR_011323). Pipettes, pulled from borosilicate glass capillaries (World Precision Instruments), had resistances between 1.5 and 2.0MΩ. Whole cell capacitance was uncompensated and leak subtraction was not used. Currents were digitized at 50kHz and filtered (4-pole Bessel) at 10kHz using pClamp10.2. Cells were positioned directly in front of a micropipette connected to a solution exchange manifold for antibody perfusion. The external solution consisted of 140mM NaCl, 5.0mM KCl, 2.0mM CaCl2, 1.0mM MgCl2, 10mM HEPES, and 11mM glucose, with a pH 7.4 by NaOH. The internal solution consisted of 62.5mM CsCl, 75mM CsF, 2.5mM MgCl2, 5mM EGTA, and 10mM HEPES, with a pH 7.25 by CsOH. To record from closed/resting channels, cells were held at -120mV and pulsed to -10mV for 30msec at 0.1Hz. To record from partially inactivated channels, cells were held at -120mV initially and then switched to a voltage that yielded 20% channel inactivation. 30msec pulses to -10 mV were delivered every 10 sec, and peak inward currents were recorded before and after antibody addition. To record from slow inactivated Na ~V~1.7 channels (P1) and following a train of depolarizing stimuli (P26), cells were voltage clamped to -110 mV for 3 sec and sodium currents were elicited by a train of 26 depolarizations of 150msec duration to -10 mV at a frequency of 5Hz. Cells were then clamped to -20mV while 500 nM rSVmab1, isotype-matched murine IgG1/kappa monoclonal antibody derived from an unrelated immunization campaign or 0.3% BSA control was added. At the 5 and 15 minute time points post-antibody addition, cells were reclamped to -110 mV for 3sec and put through the same 26 pulse voltage protocol as above. Peak inward current during the 1 ^st^ (slow inactivated) or 26 ^th^ (use-dependent) pulse to -10 mV in the presence of antibody was divided by the peak inward current evoked by the 1 ^st^ or 26 ^th^ pulse to -10 mV in the absence of antibody to determine percent inhibition. A separate use-dependent protocol was also employed that replicated conditions used by Lee *et al.* ^[@ref-6]^, where cells were held at -120mV and sodium currents were elicited by a train of depolarizations of 30msec duration to -10mV at a frequency of 10Hz. All testing solutions had 0.3% BSA (Sigma-Aldrich, \#A2058) to prevent non-specific adhesion of proteins to tubing and recording chamber components, and solutions were perfused over cells at 1ml/min. The pore blocker tetrodotoxin (TTX; 500 nM; Alomone Labs, \#T-550) was added at the end of experiments as a positive control for robust Na ~V~1.7 inhibition. Data were analyzed with pCLAMP and all figures were plotted using Origin Pro8 (OriginLab Corp).

Statistical analysis
--------------------

Electrophysiology data are presented as mean ± SEM, and statistical significance was determined using two-tailed, paired or unpaired Student\'s *t*-test with Origin Pro 8 software, with p\<0.05 denoting statistical significance.

Results
=======

Recombinant SVmab1 (rSVmab1) was purified from transiently transfected HEK293 6E cells and analyzed by SDS-PAGE ( [Figure 1A](#f1){ref-type="fig"}) and SEC-HPLC ( [Figure 1B](#f1){ref-type="fig"}). rSVmab1 migrated at an observed molecular weight of \~150kDa in non-reducing SDS-PAGE, comprised distinct and appropriately sized heavy chain and light chain bands in reducing SDS-PAGE, and eluted as a single sharp peak in SEC-HPLC. Collectively, these findings are consistent with the production of an intact antibody. Mass spectrometry analysis of non-reduced rSVmab1 revealed the major peak mass to be 147,938Da, which closely matched the theoretical mass of 147,936Da for an agalactosylated/fucosylated bi-antennary glycoprotein ( [Figure 2](#f2){ref-type="fig"}).

![Analysis of rSVmab1.\
( **A**) SDS-PAGE of 0.5 and 5.0 ug non-reduced and reduced rSVmab1. ( **B**) Size exclusion chromatography-high performance liquid chromatography elution profile of rSVmab1. The main peak comprised 97.7% of the area.](f1000research-5-10689-g0000){#f1}

![rSVmab1 evaluation by mass spectrometry.\
The major glycoform on non-reduced rSVmab1 is G0F (agalactosylated/fucosylated bi-antennary glycan) with a calculated mass of 147,938Da. Glycosylation of each heavy chain is denoted (G0F) ~2~. Additional peaks not matching the theoretical mass of 147,936Da are extended glycoforms of the intact molecule and correspond to addition of galactoses (G1F = +1 galactose; G2F= +2 galactose) or aglyco = no glycan.](f1000research-5-10689-g0001){#f2}

rSVmab1 binding to antigenic peptide was evaluated in an ELISA assay using peptide VELFLADVEG conjugated to BSA via an N-terminal cysteine residue. At 200nM rSVmab1, no peptide binding was observed, whereas binding of a positive control monoclonal antibody generated against this exact same peptide sequence was detected at a concentration as low as 2nM ( [Figure 3](#f3){ref-type="fig"}; Dataset 1). Next, purified DII voltage sensor domain protein, housing the SVmab1 epitope, was prepared as a detergent micelle in DDM and tested for rSVmab1 binding in an ELISA assay. At 13nM rSVmab1, no DIIS binding was observed, whereas binding of the positive control antibody, described above, was detected at concentrations \<1nM ( [Figure 4](#f4){ref-type="fig"}; Dataset 2). Finally, FACS was used to assess rSVmab1 binding to HEK293, CHO-K1, and U-2 OS cells expressing human Na ~V~1.7 protein. At 33nM rSVmab1, no cell binding was observed, whereas binding of a positive control Na ~V~1.7 Ab was detected in all three cell lines ( [Figure 5](#f5){ref-type="fig"}; Dataset 3).

![rSVmab1 does not bind to human Na ~V~1.7 DII voltage sensor domain S3-S4 peptide.\
Peptide ELISA of increasing concentrations of rSVmab1 (blue circles) or positive control antibody (red squares) binding to the BSA-conjugated peptide VELFLADVEG. Absorbance values after subtraction of non-specific binding to uncoated plates represent means ± standard deviation of the mean of at least two independent experiments.](f1000research-5-10689-g0002){#f3}

![rSVmab1 does not bind to the soluble DII voltage sensor domain from human Na ~V~1.7.\
ELISA analysis of increasing concentrations of rSVmab1 (blue circles) or positive control antibody (red squares) binding to purified, soluble Na ~V~1.7 DII voltage sensor domain. Absorbance values after subtraction of non-specific binding to uncoated plates represent means ± standard deviation of the mean of at least two independent experiments.](f1000research-5-10689-g0003){#f4}

![rSVmab1 does not bind to cell lines expressing human Na ~V~1.7 by FACS.\
FACS histograms of rSVmab1, positive control Na ~V~1.7 antibody (Millipore, \#MABN41), and an isotype control (R&D, \#MAB002) (all at 33nM) binding to cell lines stably or transiently expressing human Na ~V~1.7, or their respective parental cell lines.](f1000research-5-10689-g0004){#f5}

rSVmab1 was evaluated for functional inhibition of human Na ~V~1.7 currents in HEK293 cells using whole cell manual patch clamp electrophysiology. Protocols that mimic conditions reported by Lee *et al.* ^[@ref-6]^, as well as protocols that interrogate diverse Na ~V~1.7 gating states, were employed. Na ~V~ channels exist in resting/closed states where the pore is shut, open states where sodium ions can permeate the pore, and one or more inactivated states where channels are recalcitrant to opening ^[@ref-5]^. When 100nM rSVmab1 was applied to cells which were voltage clamped to a holding potential of -120mV with a 0.1Hz stimulation frequency, where Na ~V~1.7 channels are in the closed/resting state, no reduction of sodium current was detected following 20min of antibody treatment ( [Figure 6](#f6){ref-type="fig"}; Dataset 4; p\>0.05 comparing BSA control to rSVmab1). Notably, the pore blocker tetrodotoxin (TTX) robustly inhibited currents under these conditions. For comparison, 100 nM SVmab1 was reported to block closed/resting Na ~V~1.7 by \~40% at 0.1Hz ( [Figure 3D](#f3){ref-type="fig"} of the study by Lee *et al.* ^[@ref-6]^). Increasing the concentration of rSVmab1 to 500nM for 20min resulted in reductions of Na ~V~1.7 current by 40% compared to reductions of 20% with an IgG1 isotype control (p=0.05 comparing rSVmab1 to IgG1 isotype control). rSVmab1 and IgG1 isotype control both yielded significantly larger current reductions compared to a BSA vehicle control group ( [Figure 7](#f7){ref-type="fig"}; Dataset 5; p\<0.01 for BSA compared to IgG1 isotype control and p\<0.01 for BSA compared to rSVmab1). Conductance-voltage relationships ( [Figure 7](#f7){ref-type="fig"}; Dataset 5) and steady-state fast inactivation curves ( [Figure 8](#f8){ref-type="fig"}; Dataset 6) demonstrated that rSVmab1 did not affect Na ~V~1.7 gating properties. rSVmab1 was next evaluated in a use-dependent protocol using a 10Hz train of depolarizing stimuli (as per Lee *et al.* ^[@ref-6]^) to repeatedly cycle Na ~V~1.7 through open and inactive conformations in order to expose the SVmab1 epitope in the DII voltage sensor paddle region. Both 500nM rSVmab1 and an isotype control IgG1 antibody reduced tonic Na ~V~1.7 current 30--35% in the first pulse of the train with nominal evidence of use-dependent block in later pulses of the train ( [Figure 9](#f9){ref-type="fig"}; Dataset 7; p\>0.05 for all group comparisons). In all these studies, antibodies were incubated on cells for 20min with constant perfusion to accommodate a potentially slow on-rate. For comparison, 100nM SVmab1 was reported to block Na ~V~1.7 current over 80% within 10sec ( [Figure 3C](#f3){ref-type="fig"} of the study by Lee *et al.* ^[@ref-6]^), using this 10Hz protocol.

![Effect of rSVmAb1 on human Na ~V~1.7 channels in the resting/closed state when tested at 100 nM.\
( **A**) Exemplary raw traces showing sequential addition of 0.3% bovine serum albumin (BSA) control, 100 nM rSVmab1 (after 20min incubation), and 500nM tetrodotoxin (TTX) on Na ~V~1.7 currents in the same HEK293 cell. ( **B**) Summary of normalized Na ~V~1.7 currents. rSVmab1 did not block Na ~V~1.7 currents, whereas 500nM TTX robustly blocked Na ~V~1.7 currents. Data are mean ± SEM (n=3/group). ( **C**) Voltage protocol used, where channels were held at -120 mV in the closed/resting state.](f1000research-5-10689-g0005){#f6}

![Effect of rSVmab1 on human Na ~V~1.7 channels in the resting/closed state when tested at 500nM.\
( **A**-- **F**) Traces and I-V curves following control or 20min incubation with ( **A** and **D**) 0.3% bovine serum albumin (BSA), ( **B** and **E**) 500nM IgG, and ( **C** and **F**) 500 nM rSVmab1. ( **G**-- **I**) Conductance-voltage relationships following control or 20 min incubation with ( **G**) 0.3% BSA, ( **H**) 500 nM IgG, and ( **I**) 500 nM rSVmab1. ( **J**) Voltage protocol used for panels **A**-- **F**. ( **K**) Summary of normalized peak Na ~V~1.7 currents from cells incubated with 0.3% BSA, 500 nM IgG, or 500 nM rSVmab1 (after 20 min incubation) followed by 500nM tetrodotoxin (TTX), which blocked nearly all current. Data are mean ± SEM (n=5--8/group). \*\* p\<0.01 for BSA compared to IgG and BSA compared to rSVmab1 at 20 min.](f1000research-5-10689-g0006){#f7}

![Effect of rSVmab1 on human Na ~V~1.7 fast inactivation.\
Steady state fast inactivation curves following control or 20min incubation with ( **A**) 0.3% bovine serum albumin (BSA), ( **B**) 500nM IgG, and ( **C**) 500nM rSVmab1. Data are mean ± SEM (n=4--5/group). ( **D**) Voltage protocol used for panels **A**-- **C**.](f1000research-5-10689-g0007){#f8}

![Effect of rSVmab1 on human Na ~V~1.7 channels following a 10Hz use-dependent protocol.\
Normalized current over 100 pulses at 10Hz following control or 20min incubation with ( **A**) 0.3% bovine serum albumin (BSA), ( **B**) 500nM IgG, and ( **C**) 500nM rSVmab1. ( **D**) Voltage protocol used for panels **A**-- **C**. Exemplary raw traces at pulse 1 (P1) and pulse 100 (P100) following control or 20min of incubation with ( **E**) 0.3% BSA, ( **F**) 500nM IgG, and ( **G**) 500nM rSVmab1. Summary of normalized currents at P1 (tonic block) and P100 (use-dependent block) following 20 min incubation with ( **H**) 0.3% BSA, ( **I**) 500 nM IgG, and ( **J**) 500nM rSVmab1. Data are mean ± SEM (n=3--5/group).](f1000research-5-10689-g0008){#f9}

rSVmab1 was further evaluated using voltage protocols that place Na ~V~1.7 channels in various inactivated states. When cells were voltage clamped at a potential that yielded 20% Na ~V~1.7 inactivation, in which 20% of Na ~V~1.7 channels are unavailable for opening and 80% of Na ~V~1.7 channels are closed/resting, 500nM rSVmab1 and isotype control antibody decreased currents similarly around 30% after 15min of antibody treatment (p\>0.05 for BSA, IgG1, and rSVmab1 comparisons), whereas TTX robustly blocked currents within seconds of application ( [Figure 10](#f10){ref-type="fig"}; Dataset 8). When cells were evaluated using a protocol that promotes transition of Na ~V~1.7 into a slow inactivated state, by maintaining cells at a resting potential of -20mV during antibody addition and between voltage measurements, 500nM rSVmab1 and isotype control IgG1 Ab both decreased currents \~35% after 15 min, whereas TTX again robustly blocked currents ( [Figure 11](#f11){ref-type="fig"}, P1 tonic measurements; Dataset 9; p\>0.05 for BSA, IgG1, and rSVmab1 group comparisons). Layering on a 5 Hz use-dependent protocol with 150msec depolarizing pulses following induction of slow inactivation resulted in current reduction by \~65% for rSVmab1 and isotype control IgG1 groups after 15min of antibody treatment ( [Figure 11](#f11){ref-type="fig"}, P26 use measurements; Dataset 9; p\<0.01 for BSA compared to IgG1, p\<0.05 for BSA compared to rSVmab1, p\>0.05 for IgG1 compared to rSVmab1). In these experiments, effects of rSVmab1 were similar to those of the isotype control IgG1 antibody.

![Effect of rSVmab1 on partially inactivated human Na ~V~1.7 channels.\
Exemplary raw traces following control or 15min incubation with ( **A**) 0.3% bovine serum albumin (BSA), ( **B**) 500 nM IgG, and ( **C**) 500nM rSVmab1. ( **D**) Voltage-protocol used for panels **A**-- **C**. Exemplary time courses following incubation with ( **E**) 0.3% BSA, ( **F**) 500nM IgG, and ( **G**) 500nM rSVmab1. ( **H**) Voltage protocol employed for panels **E**-- **G**, where cells were held at a voltage yielding 20% channel inactivation during antibody addition. Summary of normalized currents following 15 min incubation with ( **I**) 0.3% BSA, ( **J**) 500nM IgG, and ( **K**) 500nM rSVmab1. Data are mean ±SEM (n=3--5/group).](f1000research-5-10689-g0009){#f10}

![Effect of rSVmab1 on slow inactivated human Na ~V~1.7 channels followed by a 5Hz use-dependent protocol.\
Exemplary raw traces following 5min or 15min incubation with ( **A**) 0.3% bovine serum albumin BSA, ( **B**) 500nM IgG, and ( **C**) 500nM rSVmab1. P1 = first pulse (tonic block); P26 = 26 ^th^ pulse (use-dependent block). ( **D**) Voltage protocol used for panels **A**-- **C**. Cells were clamped to -20mV during addition of antibodies and between voltage measurements. Summary of normalized currents following 5 min or 15 min incubation with 0.3% ( **E**) BSA, ( **F**) 500nM IgG, and ( **G**) 500nM rSVmab1. Data are mean ± SEM (n=4--5/group). \*\* p\<0.01 for BSA compared to IgG (15 min, P26); \* p\<0.05 for BSA compared to rSVmab1 (15 min, P26).](f1000research-5-10689-g0010){#f11}

Conclusion
==========

At the concentrations tested, recombinant monoclonal antibody SVmab1, generated from published sequence information ^[@ref-8]^, did not bind to the following target sources: Na ~V~1.7 peptide VELFLADVEG, Na ~V~1.7 DII voltage sensor protein, and Na ~V~1.7 expressing mammalian cells (HEK293, CHO-K1, U-2 OS). Recombinant SVmab1 also did not specifically block Na ~V~1.7 currents in HEK293 cells, as assessed by whole cell manual patch clamp electrophysiology when channels were closed/resting, inactivated, or cycled through states to expose the voltage sensor paddle region using a train of depolarizing stimuli. Reductions in Na ~V~1.7 current were comparable when using an isotype control IgG1 or recombinant SVmab1 at 500nM. It is unknown why both isotype control IgG1 and recombinant SVmab1 produced current reductions larger than BSA vehicle control in some voltage protocols. In the absence of positive binding data or specific Na ~V~1.7 block, our results indicate that recombinant SVmab1 is not a robust large molecule Na ~V~1.7 antagonist. It should be noted that Lee *et al.* ^[@ref-6]^ utilized SVmab1 purified from a hybridoma, whereas the studies reported here employed recombinant SVmab1 purified from HEK293 6E cells. Differences in heavy and/or light chain antibody sequences from these sources could account for the observed differences in Na ~V~1.7 binding and block. In addition, it is conceivable that differences in Na ~V~1.7 glycosylation or beta subunit expression in HEK293 cells could impact epitope accessibility to SVmab1 in cell-based experiments; beta subunits have been reported to partially mask interactions between peptide toxins and Na ~V~1.2 ^[@ref-11],\ [@ref-12]^. Other groups evaluating SVmab1 are encouraged to share their findings on Na ~V~1.7 binding and block to inform the research community on the utility of this reagent.

Data availability
=================

The data referenced by this article are under copyright with the following copyright statement: Copyright: © 2016 Liu D et al.

Open Science Framework: Dataset: Evaluation of recombinant monoclonal antibody SVmab1 binding to Na ~V~1.7 target sequences and block of human Na ~V~1.7 currents, doi [10.17605/osf.io/4jbz7](http://dx.doi.org/10.17605/osf.io/4jbz7) ^[@ref-13]^.
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This is an important study that attempts to reproduce results obtained with a putative Na ~v~1.7 blocking antibody. Na ~v~1.7 sodium channels have become major targets for reducing nociceptive signal transmission.  Lee *et al.* (2014) reported generation of a monoclonal antibody that binds to the S3-S4 linker of the Na ~v~1.7 domain II voltage sensor, blocking channel activation and providing pain and itch relief in animals. Here Liu *et al.* used the publicly available sequence information to generate recombinant SVmab1 antibody. They rigorously characterized their antibody. Surprisingly, the antibody did not seem to bind the target immunogen, voltage-sensor or full length Na ~v~1.7 channels, nor did it block Na ~v~1.7 currents. This raises many important questions. The authors appropriately discuss several reasons that their results may differ from that obtained with the original SVmab1. The array of electrophysiological experiments carried out in order to detect rSVmab1 activity is impressive, but a few additions to the paper would have been helpful. The lack of activity for recombinant SVmab1 raises concern about the original study and it would have been good to see if an aliquot of the original preparation from Lee *et al.* acted differently in their hands, but presumably aliquots of the original antibody are not available to the authors. Clarification of this point would have been helpful.Multiple studies have identified the S3-S4 linker of the Na ~v~1.7 domain II voltage sensor as critical molecular determinants of the action of peptide toxins that modulate Na ~v~1.7 activity. Indeed, Huwentoxins I and IV and Protoxin II seem to target the very peptide region that SVmab1 reportedly targets ( Schmalhofer *et al.*, 2008; Sokolov *et al.*, 2008; Xiao *et al.*, 2008, 2010). Discussion of the mechanism of action of these toxins that inhibit Na ~v~1.7 might have been helpful.The authors generated a monoclonal antibody against the sequence putatively targeted by SVmab1. Because this control antibody did bind Na ~v~1.7 in their cell lines and this peptide contains multiple major molecular determinants of HWTX-IV inhibition of Na ~v~1.7 (Xiao *et al.*, 2011), it is important to know if the control antibody inhibits Na ~v~1.7 currents.

Overall, this is a very interesting study. While it does not directly determine whether the voltage sensor of domain II of Na ~v~1.7 is a good target for inhibiting Na ~v~1.7 currents, it does raise questions about how the original SVmab1 antibody reported in Lee *et al.* (2014) was able to inhibit Na ~v~1.7 currents and if binding to Na ~v~1.7 domain II was indeed important for reducing pain and itch behaviors in that study.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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The paper by Liu *et al.* describes the production and evaluation of a recombinant version of rSVmab1, a monoclonal antibody that was recently described to bind to the Na ~v~1.7 DII voltage sensor domain, resulting in block of Na ~v~1.7 sodium currents and reduction of pain and itch in rodent models (Lee *et al.,* 2014). Interesting and surprisingly,  Liu *et al*., show that recombinant SVmab1, produced with the aid of publically available sequence information, does [not]{.ul} bind either peptide immunogen, purified Na ~v~1.7 DII voltage sensor domain, or Na ~v~1.7 in live HEK293, U-2 OS, and CHO-K1 cells. Consistent with the lack of binding, they further show that rSVmab has no specific effect on Na ~v~1.7 currents measured in patch clamp studies employing protocols that interrogate a variety of Na ~v~1.7 gating states. The study seems to have been conducted in a careful and thorough manner. In our opinion, the results conclusively show that recombinant SVmab, produced according to published sequence information, does not bind to, or inhibit Na ~v~1.7, and therefore does not represent a valid tool for the exploration of Na ~v~1.7 biology.

These findings raise the important question as to why results with the recombinant form of the antibody differ so drastically from published results with SVmab purified from hybridoma. One possibility, alluded to by Liu *et al*, is that the published sequence is different from the mAb purified from the hybridoma. If the authors have access to the original hybridoma-derived SVmab, it would be interesting to see side-by-side studies with the two forms of the antibody (alternatively, it would be interesting to hear from Lee *et al*., if they already have these comparative data at hand). Although unlikely, another possibility suggested by Liu *et al*, is that differences exist in Na ~v~1.7 glycosylation or beta subunit expression in the HEK293 cell lines utilized in the two studies. Since Lee *et al*., demonstrated that SVmab could block sodium currents (presumably Na ~v~1.7) in small DRG neurons, it might be informative to know whether the recombinant SVmab was similarly able to block these native Na ~v~1.7-mediated currents.

The original findings by Lee *et al*, indicated that mAbs directed to the DII VSD might represent a viable strategy for inhibiting Na ~v~1.7 function. Unfortunately the rSVmab described in the present study is not a useful tool for further examination of this strategy. Interestingly however, Liu *et al.*, show that the "positive control" mAb from Abmart, binds with high affinity to the peptide immunogen and the purified Na ~v~1.7 DII voltage sensor domain. It would be very interesting to know if this control mAb could inhibit Na ~v~1.7 function in patch-clamp studies.

Minor points: rSVmab was tested at 200nM in the peptide ELISA, 13nM in the DII VSD ELISA, 33nM in the FACs assays and up to 500nM in the patch clamp studies. Why was the rSVmab tested at different concentrations in each study and why was binding not assessed at concentrations used in the functional studies?Page 4 & 5. Should 8x6 ^10^ and 3x6 ^10^ be 8x10 ^6^ and 3x10 ^6^?Why was no capacitance or series resistance compensation applied in the patch clamp studies? Please provide an estimate of typical series resistance values and associated voltage-errors.Please provide more information on "MABN41". Does this mAb recognize the DII VSD or a different extracellular epitope?The recombinantly produced rSVmab was flash frozen following purification and prior to testing. Although many proteins tolerate freezing and thawing, including antibodies, there are some that do not, and this is a relatively minor variable worth considering. 

We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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This paper, by Dong Liu *et al*., represents a solid re-evaluation of the recombinant monoclonal antibody, named SVmab1, that was previously reported in the journal Cell (Lee *et al*., 2014) to selectively block human Nav1.7 channels in-vitro and inhibit pain behavior in-vivo.  The experiments described in this paper demonstrate that SVmab1, when expressed and purified from HEK293 cells, is not able to block Nav1.7 channels using several distinct voltage-activation protocols.  This antibody is also not able to bind to the same peptide antigen that it was reportedly raised against (Lee *et al.*, 2014), nor does it bind to the purified Nav1.7 domain II voltage-sensing domain (VSD2), nor cells expressing Nav1.7.  The experiments described in this paper were carried out with high accuracy and with the appropriate controls and described in sufficient detail in the paper.  The patch clamp analysis was especially exhaustive, testing the antibody using multiple voltage protocols covering close-state binding, partially inactivated binding, slow-inactivated binding, and use-dependent binding.  I am especially confident in these results since we have conducted a similar analysis of expressed and purified SVmab1 antibody at Genentech and also failed to detect binding or Nav1.7 blocking activity. 

One potential concern is that the methods used to produce SVmab1 here (HEK293 cells) are different than those used by Lee *et al*., who used hybridoma expression techniques.  Perhaps there are differences in post-translational modifications between HEK293-expressed and hybridoma-expressed SVmab1, such as glycosylation, that could account for the difference in the observed effects on Nav1.7 channels.  Glycosylation differences have been previously observed when antibodies were expressed in different mammalian cell lines (Lifely *et al.*, Glycobiology. 5:813, 1995) and could in principle alter pharmacology (though probably unlikely).  Another possibility is that the sequences presented in the patent application that were used by Dong *et al.* to express SVmab1 in HEK293 cells are not correct.  This uncertainly could be resolved if the authors of Lee et al. provided detailed mass spectrometry data on their hybridoma-expressed SVmab1 and/or deposited the hybridoma to the ATCC.

It is striking that SVmab1 lacks the ability to bind to the same peptide antigen used to generate the antibody (confirmed by Genentech).  The sequence presented in the patent application is also unusual as it lacks somatic mutations in the heavy and light variable domains (VH and VL) that are normally present in potent and specific monoclonal antibodies.  Only one non-germline residue difference is found in VL at Kabat position number 96 (W96L), which is at the VJ junction and likely due to VJ junctional diversity (not somatic mutation).  Similarly, only three non-germline residues are found in VH (in CDR 3 at Kabat positions 95, 96, and 100), which are also likely the product of junctional diversity (not somatic mutation).  Otherwise the VH segment is identical to the VhJ558.53 gene in the BALB/c mouse described by Haines et al. (Mol. Immunol. 38:9, 2001).  The lack of affinity for the peptide antigen, and the lack of somatic mutations in VH and VL, again raises the possibility that an incorrect antibody sequence is presented in the patent application.

Minor comments:

1.  Dong *et al*. identified a "positive control antibody" that they used as a control in binding experiments.  This antibody was generated at Abmart (which also generated SVmab1 itself) and was expressed and purified from hybridomas (instead of HEK293 cells).  However, only peptide binding and VSD2 binding data are shown (both positive).  It would be interesting to also determine whether this antibody is able to bind to native Nav1.7 (by FACS) and/or modulate Nav1.7 (by patch clamp).

In summary, Dong *et al.* have nicely demonstrated the inability of SVmab1 to modulate Nav1.7 channels in-vitro.  These results call into question the findings of Lee *et al.,*which previously had suggested the potential for identification of monoclonal antibodies capable of selectively blocking Nav1.7 both in-vitro and in-vivo.  If the antibody sequence presented in the patent application is in error or if there are essential post-translational difference between hybridoma-expressed SVmab1 and HEK293-expressed SVmab1, it is my hope that Lee *et al.* will clarify this so that their work can be appropriate replicated.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
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